10% Owner

Chief Executive Officer

Chief Legal & Pub. Affairs Off

DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Institution	Shares	Value	Change
BlackRock	2,460,987	$548M	DECREASED
State Street	1,323,019	$294M	DECREASED
Lsv Asset Management	908,389	$202M	DECREASED
BNY Mellon	454,545	$101M	DECREASED
Nordea Investment Management AB	395,687	$87M	INCREASED

Insider	Type	Shares	Value	Date
BERKSHIRE HATHAWAY INC (10% Owner)	SELL	182,980	$37M	2026-07-31
Javier Rodriguez (Chief Executive Officer)	SELL	39,407	$8M	2026-06-15
Javier Rodriguez (Chief Executive Officer)	SELL	30,000	$6M	2026-06-15
Kathleen Alyce Waters (Chief Legal & Pub. Affairs Off)	SELL	6,455	$1M	2026-06-15
Kathleen Alyce Waters (Chief Legal & Pub. Affairs Off)	SELL	8,950	$2M	2026-06-15

Member	Type	Amount	Date
Julie Johnson (Democrat)	SALE	$1,001 - $15,000	2025-09-23
Julie Johnson (Democrat)	PURCHASE	$1,001 - $15,000	2025-09-23

DaVita Inc. (DVA) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades